Endocrine Abstracts

Objectives: Differentiated thyroid carcinoma (DTC) in pediatric patients has peculiar clinical, pathological, and molecular characteristics, making its management different from the adult patients. Our study aimed to evaluate the outcome and predictive factors for persistent disease in a large cohort of pediatric patients.Methods: We performed a multicentric Italian study, enrolling patients aged ≤18 years old, diagnosed with a DTC, since January 2...

Objectives: Studies on active surveillance (AS) for low-risk papillary thyroid carcinoma (PTC) have shown that tumors typically enlarge to some degree during youth but stabilize thereafter. However, concerns still exist regarding cases exhibiting rapid progression during observation. The present study reviewed AS outcomes since the 1990s and investigated tumor growth patterns alongside delayed conversion surgery results.Methods: Patients with low-risk PT...

Introduction: Vandetanib was the first tyrosine kinase inhibitor approved for the first line systemic treatment of progressive metastatic or locally advanced medullary thyroid carcinomas (MTC). Previous studies reported median duration of treatment (DOT) around 20 months with a subset of patients presenting long-term responses. Little is known on the impact of RET mutation status on the response duration.Objectives: To evaluate the proportion and compare...

Background: Radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients with distant metastases show poor survival rates. However, patients’ outcome can be very heterogeneous, with cases spanning from microscopic slowly growing metastases to symptomatic, rapidly progressive disease. The aim of this study was to assess the overall survival (OS) of RAI-R DTC patients with distant metastases and to identify the prognostic factors associated with OS.<p class...

Objectives: Lenvatinib was approved for the treatment of patients with radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) in Europe in 2015 and Canada in 2016. This study investigated real-world clinical outcomes in patients with RAI-R DTC initiated with 24 mg lenvatinib once daily as first-line monotherapy in Europe and Canada.Methods: A retrospective patient chart review was conducted. The study cohort comprised RAI-R DTC patients initiat...

Objectives: Radioiodine therapy with ablative purposes is less and less used in low (LR) and intermediate (IR) risk DTC patients. The aim of this prospective ongoing study is to evaluate the clinical trend over time of patients with DTC who do not receive treatment with radioiodine.Methods: Patients with high or intermediate-high risk in whom radioiodine treatment was performed after surgery were excluded. Data of 425 consecutive patients with DTC who jo...

Background: Prophylactic central neck dissection (pCND) in patients with no clinical nodal disease (cN0) is one of the major concern and ongoing controversy in thyroid surgery. However, there are no clear evidence because prospective randomized clinical tirals are still not enough to make definite recommendations. The purpose of our study was to investigate prognostic pros & cons of pCND to provide reliable evidence on this topic.Method: A total of 2...